Tuesday, IGC Pharma Inc (NYSE:IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associated with Alzheimer’s. The data demonstrates a clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results